Integer (NYSE:ITGR) Shares Gap Down to $123.27

Integer Holdings Co. (NYSE:ITGR - Get Free Report)'s share price gapped down before the market opened on Thursday . The stock had previously closed at $123.27, but opened at $114.00. Integer shares last traded at $112.86, with a volume of 342,010 shares trading hands.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ITGR. CL King initiated coverage on shares of Integer in a report on Thursday, March 14th. They issued a "buy" rating and a $137.00 price target for the company. Benchmark boosted their price objective on Integer from $105.00 to $130.00 and gave the company a "buy" rating in a research note on Thursday, March 28th. Bank of America upgraded Integer from a "neutral" rating to a "buy" rating and upped their target price for the company from $105.00 to $135.00 in a report on Monday, April 15th. Finally, KeyCorp lifted their target price on Integer from $123.00 to $139.00 and gave the company an "overweight" rating in a research note on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $120.50.

Integer Stock Performance

The firm has a market capitalization of $3.73 billion, a price-to-earnings ratio of 41.36, a PEG ratio of 1.63 and a beta of 1.10. The stock's 50-day moving average is $112.91 and its 200-day moving average is $99.57. The company has a current ratio of 2.80, a quick ratio of 1.71 and a debt-to-equity ratio of 0.64.

Integer (NYSE:ITGR - Get Free Report) last announced its quarterly earnings data on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.05. Integer had a return on equity of 10.80% and a net margin of 5.68%. The firm had revenue of $413.15 million for the quarter, compared to analysts' expectations of $409.04 million. During the same period last year, the firm earned $1.11 earnings per share. The company's revenue for the quarter was up 10.9% compared to the same quarter last year. On average, analysts predict that Integer Holdings Co. will post 5.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Blue Trust Inc. lifted its stake in Integer by 483.3% during the fourth quarter. Blue Trust Inc. now owns 455 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 377 shares in the last quarter. Principal Securities Inc. acquired a new stake in Integer in the fourth quarter valued at about $67,000. Emerald Mutual Fund Advisers Trust grew its stake in Integer by 66.6% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 1,461 shares of the medical equipment provider's stock valued at $115,000 after acquiring an additional 584 shares during the period. Van ECK Associates Corp raised its stake in shares of Integer by 22.0% in the third quarter. Van ECK Associates Corp now owns 1,733 shares of the medical equipment provider's stock valued at $136,000 after buying an additional 313 shares during the period. Finally, Quadrant Capital Group LLC boosted its holdings in shares of Integer by 10.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,427 shares of the medical equipment provider's stock worth $141,000 after purchasing an additional 132 shares in the last quarter. 99.29% of the stock is owned by hedge funds and other institutional investors.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.